Brentuximab Vedotin in First Refractory/Relapsed Classical Hodgkin Lymphoma Patients Treated By Chemotherapy ( ICE) before Autologous Transplantation. Final Analysis of Phase II Study

被引：0
|
作者：
Stamatoullas, Aspasia [1 ]
Ghesquieres, Herv [2 ]
Filliatre, Lauriane Clement [3 ]
Quittet, Philippe [4 ]
Morschhauser, Franck [5 ]
Ribrag, Vincent [6 ]
Edeline, Veronique [7 ]
Brice, Pauline [8 ]
机构：
[1] Ctr Henri Becquerel, Dept Hematol, Rouen, France
[2] Ctr Hosp Lyon Sud, Dept Hematol, Pierre Benite, France
[3] CHRU, Vandoeuvre Les Nancy, France
[4] CHU St Eloi, Dept Hematol, Montpellier, France
[5] Hop Claude Huriez, CHRU Lille, Lille, France
[6] Gustave Roussy, Villejuif, France
[7] Hop Rene Huguenin, Serv Med Nucl, Inst Curie, St Cloud, France
[8] Hop St Louis, Paris, France
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
132
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Brentuximab Vedotin in First Refractory/Relapsed Classical Hodgkin Lymphoma Patients Treated By Chemotherapy ( ICE) before Autologous Transplantation. Final Analysis of Phase II Study
    Stamatoullas, Aspasia
    Ghesquieres, Herv
    Filliatre, Lauriane Clement
    Quittet, Philippe
    Morschhauser, Franck
    Ribrag, Vincent
    Edeline, Veronique
    Brice, Pauline
    BLOOD, 2019, 134
  • [2] Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma
    Forlenza, Christopher J.
    Rosenzweig, Jaclyn
    Mauguen, Audrey
    Buhtoiarov, Ilia
    Cuglievan, Branko
    Dave, Hema
    Deyell, Rebecca J.
    Flerlage, Jamie E.
    Franklin, Anna K.
    Krajewski, Jennifer
    Leger, Kasey J.
    Marks, Lianna J.
    Norris, Robin E.
    Pacheco, Martha
    Willen, Faye
    Yan, Adam Paul
    Harker-Murray, Paul D.
    Giulino-Roth, Lisa
    BLOOD ADVANCES, 2023, 7 (13) : 3225 - 3231
  • [3] Economic Burden in US Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Brentuximab Vedotin or Chemotherapy after Failure of Autologous Hematopoietic Cell Transplantation
    Chen, Clara
    Johnston, Karissa
    Szabo, Shelagh
    Connors, Joseph M.
    Yasenchak, Christopher A.
    BLOOD, 2017, 130
  • [4] Phase II Study of Brentuximab Vedotin Plus Ibrutinib for Patients with Relapsed/Refractory Hodgkin Lymphoma
    Chen, Robert W.
    Palmer, Joycelynne M.
    Herrera, Alex Francisco
    Armenian, Saro H.
    Mei, Matthew
    Popplewell, Leslie
    Fueger, Abbey
    Qasim, Imran
    Stiller, Tracy
    Rosen, Steven T.
    Forman, Stephen J.
    Kwak, Larry W.
    BLOOD, 2017, 130
  • [5] Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma
    Chen, Robert
    Palmer, Joycelynne M.
    Martin, Peter
    Tsai, Nicole
    Kim, Young
    Chen, Bihong T.
    Popplewell, Leslie
    Siddiqi, Tanya
    Thomas, Sandra H.
    Mott, Michelle
    Sahebi, Firoozeh
    Armenian, Saro
    Leonard, John
    Nademanee, Auayporn
    Forman, Stephen J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (12) : 2136 - 2140
  • [6] Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
    Younes, Anas
    Gopal, Ajay K.
    Smith, Scott E.
    Ansell, Stephen M.
    Rosenblatt, Joseph D.
    Savage, Kerry J.
    Ramchandren, Radhakrishnan
    Bartlett, Nancy L.
    Cheson, Bruce D.
    de Vos, Sven
    Forero-Torres, Andres
    Moskowitz, Craig H.
    Connors, Joseph M.
    Engert, Andreas
    Larsen, Emily K.
    Kennedy, Dana A.
    Sievers, Eric L.
    Chen, Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (18) : 2183 - 2189
  • [7] Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation
    Kaloyannidis, Panayotis
    Hertzberg, Mark
    Webb, Kate
    Zomas, Athanasios
    Schrover, Rudolf
    Hurst, Michael
    Jacob, Ian
    Nikoglou, Thalia
    Connors, Joseph M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 188 (04) : 540 - 549
  • [8] Combination of Brentuximab Vedotin and Pembrolizumab as Salvage Treatment Before Autologous Stem Cell Transplantation and Maintenance in Patients with Relapsed/Refractory Hodgkin Lymphoma
    Massa, Hanne
    Massaro, Fulvio
    Maerevoet, Marie
    BIOMEDICINES, 2025, 13 (02)
  • [9] Brentuximab Vedotin Plus Bendamustine in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: A Meta-Analysis
    Abdelgawad, Hussien Ahmed H.
    Belal, Mohamed Mohamed
    Bashir, Mohamed Nabih
    Aboeldahab, Heba
    Eshun, Francis
    Otto, Mario
    Henry, Michael
    BLOOD, 2023, 142
  • [10] Promising remissions in relapsed refractory classical Hodgkin lymphoma patients requiring multiple salvage regimens before transplantation in the brentuximab vedotin era
    Abuelgasim, Khadega A.
    Ghazi, Samer
    Alahmari, Bader
    Alhejazi, Ayman
    Alaskar, Ahmed
    Alzahrani, Mohsen
    Damlaj, Moussab
    LEUKEMIA RESEARCH REPORTS, 2021, 16
12345